{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:26:04Z","timestamp":1791239164927,"version":"4.1.0"},"reference-count":200,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jdiacomp.2021.108101","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T20:14:26Z","timestamp":1638908066000},"page":"108101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases"],"prefix":"10.1016","volume":"36","author":[{"given":"Yehuda","family":"Handelsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Jellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Lepor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin D.","family":"Michos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam R.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2021.108101_bb0005","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease surveillance system\u2014United States; https:\/\/nccd.cdc.gov\/CKD\/. Accessed 19 November 2019."},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0010","series-title":"National diabetes statistics report, 2017","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0015","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.07891109","article-title":"Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes","volume":"5","author":"Plantinga","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0020","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the american Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0030","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the american Association of Clinical Endocrinologists and American College of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm\u20142020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0035","article-title":"KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0040","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Causes of Death Collaborators","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0045","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/heartjnl-2016-309573","article-title":"Trends in the epidemiology of cardiovascular disease in the UK","volume":"102","author":"Bhatnagar","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0050","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ajcn\/76.1.93","article-title":"Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and nutrition examination survey epidemiologic follow-up study","volume":"76","author":"Bazzano","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/nu11020338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0070","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s13300-021-01086-y","article-title":"Episodic real-time CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial","volume":"12","author":"Price","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0075","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/dia.2020.0396","article-title":"Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic","volume":"23","author":"Bergenstal","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0080","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/eurheartj\/ehr007","article-title":"Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies","volume":"32","author":"Cappuccio","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/oby.2000.31","article-title":"Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients","volume":"8","author":"Valencia-Flores","year":"2000","journal-title":"Obes Res"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0090","author":"American Heart Association"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0095","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jep.13349","article-title":"Meaningful shared decision-making: complex process demanding cognitive and emotional skills","volume":"26","author":"Stalnikowicz","year":"2020","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0100","first-page":"109","article-title":"Motivational interviewing: an evidence-based approach for use in medical practice","volume":"118","author":"Bischof","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6296896","article-title":"Effectiveness of smartphone-based physical activity interventions on individuals\u2019 health outcomes: a systematic review","volume":"2021","author":"Emberson","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12966-016-0454-y","article-title":"Efficacy of interventions that use apps to improve diet, physical activity and sedentary behaviour: a systematic review","volume":"13","author":"Schoeppe","year":"2016","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0115","doi-asserted-by":"crossref","DOI":"10.2196\/11819","article-title":"Consumer-based wearable activity trackers increase physical activity participation: systematic review and meta-analysis","volume":"7","author":"Brickwood","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.7326\/L19-0524","article-title":"Cardiovascular events and mortality in white coat hypertension","volume":"171","author":"Cohen","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11886-016-0780-3","article-title":"Integrating out-of-office blood pressure in the diagnosis and management of hypertension","volume":"18","author":"Cohen","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0130","article-title":"7. Diabetes technology: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eprac.2021.04.008","article-title":"American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus","volume":"27","author":"Grunberger","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.diabres.2012.03.002","article-title":"Results that matter: structured vs. Unstructured self-monitoring of blood glucose in type 2 diabetes","volume":"97","author":"Parkin","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0145","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0150","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0155","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0165","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1210\/jc.2008-1348","article-title":"Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose","volume":"94","author":"Dagogo-Jack","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0170","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/1535370220915644","article-title":"Regression from prediabetes to normal glucose regulation: state of the science","volume":"245","author":"Sallar","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0175","article-title":"8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0180","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0185","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.28.4.888","article-title":"Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program","volume":"28","author":"Diabetes Prevention Program Research Group","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0190","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0195","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0200","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/1573399816666191230113446","article-title":"Liraglutide therapy in a prediabetic state: rethinking the evidence","volume":"16","author":"Papaetis","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0210","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0215","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/WNL.51.3.728","article-title":"The incidence of dementia: a meta-analysis","volume":"51","author":"Jorm","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0220","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cger.2014.04.001","article-title":"Dementia and cognitive impairment: epidemiology, diagnosis, and treatment","volume":"30","author":"Hugo","year":"2014","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0225","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jdi.12087","article-title":"Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies","volume":"4","author":"Gudala","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-132363","article-title":"Heart diseases and long-term risk of dementia and Alzheimer's disease: a population-based CAIDE study","volume":"42","author":"Rusanen","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0235","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2009.460","article-title":"Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus","volume":"301","author":"Whitmer","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0240","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13607863.2014.915924","article-title":"Hearing loss and dementia\u2014who is listening?","volume":"18","author":"Lin","year":"2014","journal-title":"Aging Ment Health"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0245","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and progress in Alzheimer's Disease\u2014FDA approval of aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6660930","article-title":"A systematic review and meta-analysis of risk factors associated with severity and death in COVID-19 patients","volume":"2021","author":"Du","year":"2021","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021\u201322 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0260","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0265","author":"Immunization Action Coalition"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0270","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/CIRCULATIONAHA.121.057534","article-title":"Am I getting the influenza shot too?: influenza vaccination as post-myocardial infarction care for the prevention of cardiovascular events and death","volume":"144","author":"Michos","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jdiacomp.2021.108101_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2188","article-title":"Intricate interplay between COVID-19 and cardiovascular diseases","volume":"31","author":"Keri","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0280","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/CIRCULATIONAHA.120.050354","article-title":"Severe COVID-19 is a microvascular disease","volume":"142","author":"Lowenstein","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0285","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13054-021-03461-4","article-title":"Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19","volume":"25","author":"Hultstr\u00f6m","year":"2021","journal-title":"Crit Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0290","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019636","article-title":"Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis","volume":"10","author":"Yedlapati","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0295","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3S","key":"10.1016\/j.jdiacomp.2021.108101_bb0300","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jmir.2021.08.014","article-title":"Coronary computed tomographic angiography: a review of the techniques, protocols, pitfalls, and radiation dose","volume":"52","author":"Tridandapani","year":"2021","journal-title":"J Med Imaging Radiat Sci"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12968-020-00652-w","article-title":"Exercise cardiovascular magnetic resonance: development, current utility and future applications","volume":"22","author":"Craven","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0310","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.jacc.2010.11.006","article-title":"2011 ASA\/ACCF\/AHA\/AANN\/AANS\/ACR\/ASNR\/CNS\/SAIP\/SCAI\/SIR\/SNIS\/SVM\/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease","volume":"57","author":"Brott Thomas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0315","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease","volume":"69","author":"Gerhard-Herman Marie","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0320","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the Management of Heart Failure","volume":"62","author":"Yancy Clyde","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0325","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the Management of Heart Failure","volume":"70","author":"Yancy Clyde","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0335","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0340","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0345","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0360","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","volume":"66","author":"McClelland","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0365","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjcard.2004.03.023","article-title":"Framingham risk score and prediction of lifetime risk for coronary heart disease","volume":"94","author":"Lloyd-Jones","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0370","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0375","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0380","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the american College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Goff","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0385","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40273-018-0662-1","article-title":"Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO)","volume":"36","author":"Shao","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0390","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 Working Group","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0395","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0400","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0405","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0410","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0415","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","article-title":"Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki heart study","volume":"166","author":"Tenkanen","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0425","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.2337\/dc11-s203","article-title":"The ACCORD (Action to control cardiovascular risk in Diabetes) lipid trial: what we learn from subgroup analyses","volume":"34","author":"Ginsberg","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205006","article-title":"Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: real-world results and factors associated with triglyceride reduction","volume":"13","author":"Woo","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0435","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2017.11.005","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0445","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european Society of Cardiology (ESC) and the european Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0450","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0455","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MNH.0b013e32832edc99","article-title":"Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?","volume":"18","author":"Kalaitzidis","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0460","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","article-title":"Redefining diuretics use in hypertension: why select a thiazide-like diuretic?","volume":"37","author":"Burnier","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0465","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0470","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0475","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0480","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3904\/kjim.2020.650","article-title":"Clinical features and predictors of masked uncontrolled hypertension from the korean ambulatory blood pressure monitoring registry","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0485","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0490","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0495","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0500","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0505","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jamacardio.2016.1018","article-title":"Understanding the adverse effects of ticagrelor in practice","volume":"1","author":"Granger","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0510","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0515","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0520","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0525","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0530","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0535","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0540","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0545","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0550","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0555","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0560","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0565","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0570","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0575","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0580","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0585","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0590","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0595","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0600","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0605","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0610","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0615","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0620","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0625","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0630","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0635","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0640","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0645","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0650","article-title":"6. Glycemic targets: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0655","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/clinem\/dgz087","article-title":"Results of a study comparing glycated albumin to other glycemic indices","volume":"105","author":"Desouza","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0660","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc17-1624","volume":"40","author":"Agiostratidou","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0665","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0670","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2337\/dc11-2054","article-title":"Increased mortality of patients with diabetes reporting severe hypoglycemia","volume":"35","author":"McCoy","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0675","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jval.2011.02.001","article-title":"The impact of non-severe hypoglycemic events on work productivity and diabetes management","volume":"14","author":"Brod","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0680","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/dom.13132","article-title":"Identification of barriers to insulin therapy and approaches to overcoming them","volume":"20","author":"Russell-Jones","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0685","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2337\/dc20-0097","article-title":"Differences in U.S. rural-urban trends in diabetes ABCS, 1999-2018","volume":"44","author":"Mercado","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0690","first-page":"1665","article-title":"Imputed state-level prevalence of achieving goals to prevent complications of diabetes in adults with self-reported diabetes\u2014United States, 2017\u20132018","volume":"69","author":"Chen","year":"2020","journal-title":"MMWR"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0695","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0700","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/DMSO.S20633","article-title":"Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach","volume":"4","author":"Kedia","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0705","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17425247.2019.1653278","article-title":"Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation","volume":"16","author":"Newswanger","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0710","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.933860","article-title":"Editorial: international consensus recommendations to replace the terminology of non-alcoholic fatty liver disease (NAFLD) with metabolic-associated fatty liver disease (MAFLD)","volume":"27","author":"M\u00e9ndez-S\u00e1nchez","year":"2021","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0715","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0720","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0725","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0730","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0735","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0740","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0745","doi-asserted-by":"crossref","first-page":"13058","DOI":"10.1038\/srep13058","article-title":"Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort","volume":"5","author":"K\u00e4lsch","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0750","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0755","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0760","doi-asserted-by":"crossref","first-page":"4-LB","DOI":"10.2337\/db20-4-LB","article-title":"4-LB: substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES","volume":"69","author":"Bhatt","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0765","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0770","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0775","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0780","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0785","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0790","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","article-title":"Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades","volume":"11","author":"Vasan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0800","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/VHRM.S83662","article-title":"Targeting heart failure with preserved ejection fraction: current status and future prospects","volume":"12","author":"Kanwar","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0805","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12471-016-0811-0","article-title":"How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing","volume":"24","author":"Huis In 't Veld","year":"2016","journal-title":"Neth Hear J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0810","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes","volume":"126","author":"Steinberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0815","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"issue":"12","key":"10.1016\/j.jdiacomp.2021.108101_bb0820","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/bph.13480","article-title":"Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm","volume":"173","author":"Loudon","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0825","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0830","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among us adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0835","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"de Boer","year":"2014","journal-title":"Diabetes Care"},{"issue":"9854","key":"10.1016\/j.jdiacomp.2021.108101_bb0840","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0845","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1681\/ASN.2016121372","article-title":"Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease","volume":"28","author":"Neumiller","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0850","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2021.03.008","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","author":"Delgado","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1016\/j.jdiacomp.2021.108101_bb0855","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0860","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0865","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0870","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0875","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0880","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0885","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2215\/CJN.18771220","article-title":"GLP-1 receptor agonists in diabetic kidney disease","volume":"16","author":"Michos","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0890","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0895","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0900","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0905","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcard.2016.04.127","article-title":"New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: considerations for trial design and regulatory approval","volume":"216","author":"Zannad","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0910","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0915","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2014a position statement from the heart failure Association of the European Society of cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0920","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0925","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0930","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/0022-3859.123143","article-title":"Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients","volume":"59","author":"Singh","year":"2013","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0935","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0940","first-page":"61","article-title":"The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies","volume":"8","author":"Davies","year":"2016","journal-title":"Clin Pharmacol."},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0945","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0950","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0955","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence","volume":"12","author":"Fonseca","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0960","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.002279","article-title":"Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects","volume":"1","author":"Gaziano","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0965","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0970","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0975","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014mechanistic and therapeutic effects","author":"Barrera-Chimal","year":"2021","journal-title":"Nature Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0980","article-title":"Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor","author":"Clarisse","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0985","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0990","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb0995","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2021.108101_bb1000","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022069","article-title":"Effects of sacubitril\/valsartan on serum lipids in heart failure with preserved ejection fraction","volume":"10","author":"Selvaraj","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721003251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872721003251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:15:20Z","timestamp":1761005720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872721003251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":200,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1056872721003251"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.108101","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2021.108101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108101"}}